4 Result(s)
within
C. Massard
Drug Resistance
-
Article
Open AccessA direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
Circulating tumour cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, there is no universal method to detect CTC currently available. Here, we compared the performance o...
-
Article
Open AccessA phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumour and antiangiogenic activity. We investigated the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients...
-
Article
Open AccessErratum: Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Correction to: British Journal of Cancer (2008) 97, 857–861, doi:10.1038/sj.bjc.6603942 The authors of the above paper, first published in October 2007, would like to add the following acknowledgement to their...
-
Article
Open AccessCarcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase inhibitors are promising new drugs. The aim of this study was to determine the exp...
